Literature DB >> 16244769

Endothelial cell activity in chronic obstructive pulmonary disease without severe pulmonary hypertension.

Giuseppe Cella1, Marina Saetta, Simonetta Baraldo, Graziella Turato, Alberto Papi, Gianluca Casoni, Manuela Rigno.   

Abstract

Pulmonary hypertension is common in patients with chronic obstructive pulmonary disease (COPD), but the precise mechanism of vascular impairment in these patients is unknown. We, therefore, decided to investigate whether endothelial cell dysfunction is present in patients with COPD with a wide range of chronic airflow obstruction before the development of severe pulmonary hypertension. Selected plasma markers of endothelial cell activity were studied: nitrate+nitrite (NO-(2)/NO-(3)), thrombomodulin (TM), tissue factor pathway inhibitor (TFPI), soluble selectins (endothelium sES, leukocyte sLS, platelet sPS), soluble intercellular adhesion molecule-1 (sICAM-1), and soluble platelet endothelial cell adhesion molecule-1 (sPECAM-1). Twenty-five patients with COPD (forced expiratory volume in one second/vital capacity [FEV(1)/VC] < 88% predicted) and 29 healthy control subjects were recruited to the study. Among patients nine had a pulmonary artery systolic pressure (PASP) between 15 and 30 mmHg, 13 between 32 and 38 mmHg, 2 had a PASP of 41 and 42 mmHg, respectively. One patient had severe pulmonary hypertension with a PASP of 70 mmHg. The average FEV(1) of patients with COPD was 46 +/- 4% predicted. As compared to control subjects, patients with COPD showed a significant increase in plasma levels of TM and TFPI, indicating that their endothelial cells are still able to produce potent coagulation inhibitors. Levels of NO-(2)/NO-(3) were similar in the two groups of subjects examined, further suggesting preserved endothelial function in patients with COPD. In regard to adhesion molecules, patients with COPD showed a reduction in sLS, sPS, and sPECAM-1, and an increase in sICAM-1. This study shows that endothelial cell activity is largely preserved in patients with COPD without severe pulmonary hypertension, suggesting that these patients, despite quite severe airway obstruction, retain reasonably normal endothelial function until they develop severe pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16244769     DOI: 10.1177/107602960501100410

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  5 in total

1.  Thrombin generation in chronic obstructive pulmonary disease: dependence on plasma factor composition.

Authors:  Anetta Undas; Milosz Jankowski; Przemysław Kaczmarek; Krzysztof Sladek; Kathleen Brummel-Ziedins
Journal:  Thromb Res       Date:  2011-05-31       Impact factor: 3.944

2.  Serum level of soluble intercellular adhesion molecule-1 correlates with pulmonary arterial pressure in children with congenital heart disease.

Authors:  Kanrawee Sungprem; Apichai Khongphatthanayothin; Patchara Kiettisanpipop; Pairoj Chotivitayatarakorn; Yong Poovorawan; Pornthep Lertsapcharoen
Journal:  Pediatr Cardiol       Date:  2009-01-30       Impact factor: 1.655

3.  The VICI-trial: high frequency oscillation versus conventional mechanical ventilation in newborns with congenital diaphragmatic hernia: an international multicentre randomized controlled trial.

Authors:  Lieke van den Hout; Dick Tibboel; Sanne Vijfhuize; Harma te Beest; Wim Hop; Irwin Reiss
Journal:  BMC Pediatr       Date:  2011-11-02       Impact factor: 2.125

Review 4.  The effects of extracellular matrix proteins on neutrophil-endothelial interaction--a roadway to multiple therapeutic opportunities.

Authors:  Jagannath Padmanabhan; Anjelica L Gonzalez
Journal:  Yale J Biol Med       Date:  2012-06-25

5.  A double blind randomized placebo control crossover trial on the effect of dietary nitrate supplementation on exercise tolerance in stable moderate chronic obstructive pulmonary disease.

Authors:  Paul Leong; Jane E Basham; Theresa Yong; Adrian Chazan; Paul Finlay; Sara Barnes; Phillip G Bardin; Donald Campbell
Journal:  BMC Pulm Med       Date:  2015-05-02       Impact factor: 3.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.